Delivery Order SPE2DB20D3103-SPE2DB24FM5A4
- Not listed
- This federal contract award, valued at $12,307.46, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of ADVAIR HFA 115-21 MCG INHALER 12GM, a pharmaceutical product, with a completion date of January 19, 2024. This is a Firm Fixed Price Delivery Order contract, and no set-aside designation was used. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award, valued at $4,420.92, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is a delivery order for the supply of ADVAIR HFA 230-21 MCG INHALER 12GM, a pharmaceutical product. This award is not associated with a set-aside program and was made through full and open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This federal contract award, valued at $5,139.24, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is a delivery order to provide the DLA with ADVAIR HFA 115-21 MCG INHALER 12GM, a pharmaceutical product, with a completion date of February 1, 2024. The contract does not have a set-aside designation, indicating it was a full and open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery...
- This federal contract award, valued at $14,510.21, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of ADVAIR HFA 230-21 MCG INHALER 12GM, a pharmaceutical product, with a completion date of May 1, 2024. The contract is a delivery order with a firm fixed-price pricing type. There is no set-aside designation mentioned for this award. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery...
- This federal contract award, valued at $5,819.83, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is for the delivery of ADVAIR HFA 230-21 MCG INHALER 12GM, a pharmaceutical product. It is a delivery order contract with a firm fixed price. The award is part of a larger Indefinite Delivery Contract (IDC) held by Cencora, Inc. with the DLA Troop Support Medical, valued at up to $999,999,999.00 and...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $13,630.44 firm fixed-price delivery order is for the supply of ADVAIR HFA 230-21 MCG INHALER 12GM, a pharmaceutical product. The contract has an ultimate completion date of March 11, 2024. Amerisourcebergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for...
- This federal contract award, valued at $7,547.84, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of ADVAIR HFA 115-21 MCG INHALER 8GM, a pharmaceutical product. The award has a completion date of March 7, 2022 and is a firm fixed-price delivery order. The contract does not have a set-aside designation, indicating it was awarded through full and open...
- This federal contract award, valued at $4,323.82, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of ADVAIR HFA 115-21 MCG INHALER 12GM, a pharmaceutical product, and has a completion date of March 11, 2024. The contract is a Delivery Order with a Firm Fixed Price pricing type and does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant...
- This federal contract award, valued at $7,512.22, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor, Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of ADVAIR HFA 115-21 MCG INHALER 12GM, a pharmaceutical product, with a completion date of March 11, 2024. This award is not associated with a set-aside program and was made through full and open competition. Amerisourcebergen Drug Corp, a major pharmaceutical...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $1,886.40 firm fixed-price delivery order is for the supply of ADVAIR HFA 115-21 MCG INHALER 12GM, a pharmaceutical product. The contract has an ultimate completion date of May 11, 2023. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB24FM5A4Delivery Order
This federal contract award, valued at $5,326.40, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a pharmaceutical distribution company owned by the parent organization Cencora, Inc. The award is for the delivery of an ADVAIR HFA 230-21 MCG INHALER 12GM pharmaceutical product, with a completion date of February 1, 2024. The contract is a delivery order, utilizing a firm fixed-price pricing type. It is not designated with any set-aside requirements, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026, which serves as the primary vehicle for the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. In addition, Cencora, Inc. maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.3k | 1/31/24 |